In a recent press release, GE Healthcare has announced its plans to acquire MIM Software, aiming to leverage the latter’s imaging analytics and digital workflow capabilities across various care areas. This strategic move is anticipated to accelerate innovation and differentiate GE Healthcare’s solutions, ultimately benefiting patients and healthcare systems globally.
MIM Software’s portfolio includes advanced imaging solutions offering key features such as the integration of diagnostic images from multiple modalities into treatment plans, task automation to reduce manual interventions, quantitation and advanced processing in diagnostic imaging and nuclear medicine, and a platform for assisting with Theranostics imaging and dosimetry.
The integration of MIM Software solutions into GE Healthcare’s advanced visualization offerings is expected to enhance AI-based segmentation, contouring, and dosimetry analysis for patients throughout their treatment journeys. This collaboration is particularly significant in the expanding fields of radiology, molecular imaging, and radiation oncology.
Peter Arduini, President, and CEO of GE Healthcare expressed the commitment to providing comprehensive, connected devices and digital solutions to improve patient care across multiple specialties. He stated, “We expect our efforts to bring these two complementary organizations and innovative product portfolios together to strengthen our capabilities as a leading provider of integrated imaging systems, analytics, and advanced digital workflows across several care areas and pathways.”
The CEO of MIM Software, Andrew Nelson, shared his excitement about joining GE Healthcare, emphasizing the prospect of developing new and integrated digital solutions to meet customers’ evolving needs. The acquisition aligns with GE Healthcare’s transformative goals, positioning them as a prominent provider in Theranostics, radiation oncology, urology, neurology, and cardiology.
The consummation of the transaction is subject to customary closing conditions, including regulatory approvals, with no public disclosure of financial details at this time.
